Evidence map›Paper›PMID 36268513›Full record

ArticleFrontiers in cell and developmental biology2022

Loss of the fructose transporter SLC2A5 inhibits cancer cell migration.

Jody Groenendyk, Konstantin Stoletov, Tautvydas Paskevicius, Wenjuan Li, Ning Dai, Myriam Pujol, Erin Busaan, Hoi Hei Ng, Aristeidis E Boukouris, Bruno Saleme and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 2 countries.

Jody GroenendykDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Konstantin StoletovDepartment of Oncology, University of Alberta, Edmonton, AB, Canada.
Tautvydas PaskeviciusDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Wenjuan LiDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Ning DaiDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Myriam PujolDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Erin BusaanDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Hoi Hei NgDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Aristeidis E BoukourisDepartment of Medicine, University of Alberta, Edmonton, AB, Canada.
Bruno SalemeDepartment of Medicine, University of Alberta, Edmonton, AB, Canada.
Alois HaromyDepartment of Medicine, University of Alberta, Edmonton, AB, Canada.
Kaisa CuiWuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Miao HuNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, Hubei University of Technology, Wuhan, China.
Yanan YanNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, Hubei University of Technology, Wuhan, China.
Rui ZhangNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, Hubei University of Technology, Wuhan, China.
Evangelos MichelakisDepartment of Medicine, University of Alberta, Edmonton, AB, Canada.
Xing-Zhen ChenDepartment of Physiology, University of Alberta, Edmonton, AB, Canada.
John D LewisDepartment of Oncology, University of Alberta, Edmonton, AB, Canada.
Jingfeng TangNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, Hubei University of Technology, Wuhan, China.
Luis B AgellonSchool of Human Nutrition, McGill University, Montreal, QC, Canada.
Marek MichalakDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
University of Alberta · CAHubei University of Technology · CNMcGill University · CAWuxi Fourth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastasis is the primary cause of cancer patient death and the elevation of SLC2A5 gene expression is often observed in metastatic cancer cells. Here we evaluated the importance of SLC2A5 in cancer cell motility by silencing its gene. We discovered that CRISPR/Cas9-mediated inactivation of the SLC2A5 gene inhibited cancer cell proliferation and migration

Indexed as

cancercell migrationinvadopodiametastasismitochondria

Identifiers

PMID36268513
PMCPMC9578049
OpenAlexW4298111048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.